ArticleFrontiers in public health2025
Genomic surveillance of SARS-CoV-2 in the Andean Community (2020-2024): integrating regional sequencing efforts from Colombia, Ecuador, Peru, and Bolivia through "ORAS-CONHU" program.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A comprehensive analysis of the SARS-CoV-2 omicron variant in Tocantins State, Brazil, and tracing the spread of the XBB.1.18.1 lineage.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Large-Scale Saliva-Based Clinical Surveillance Enables Real Time SARS-CoV-2 Outbreak Detection and Genomic Tracking (Arizona, 2020-2023).Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The COVID-19 pandemic has deeply affected Latin American countries, with countless COVID-19 cases and deaths. In countries like Peru, Colombia, Ecuador and Bolivia there was a collapse of the public health system, and the lack of testing capacity did not allow to control the spread of SARS-CoV-2 during the first year of the COVID-19 pandemic. After these dramatic beginnings, regional efforts focused on improving testing capacity and massive vaccinations campaigns, but also implementing a sustained SARS-CoV-2 genomic surveillance program to follow up the evolution of the virus. Methods: This study examines the regional efforts in the Andean Community in terms of SARS-CoV-2 genomic surveillance for Colombia, Ecuador, Peru, and Bolivia in coordination with "Organismo Andino de Salud-Convenio Hipólito Unanue" (ORAS-CONHU). Moreover, SARS-CoV-2 emerging lineages distribution, clade determination and phylogenetic analysis in those countries for the period 2020-2024 was done by retrieving 16,867 sequences from the GISAID database. Results: From the initial lineages 19A and 19B, lineages 20A, 20B, and 20C emerged in 2020, followed by several variants such as 20 J (Gamma), 21A (Delta), 21G (Lambda), and 21H (Mu) emergence along 2021; by the end of 2022, the highly transmissible Omicron variants (21 K, 21 L) emerged and have been evolving into multiple sub variants lineages like 22F, 23A, and 23I (JN.1), the latest dominant along 2024. Discussion: While each country exhibits some specific characteristics, the phylogenetic analysis underscored a common pattern in the lineage evolution of SARS-CoV-2 in the Andean Community supporting a rapid transnational transmission of the virus. This study was part of a regional effort to develop an integrative transnational genomic surveillance network for SARS-CoV-2 as a proxy for a more ambitious regional infectious diseases genomic surveillance program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.